3D
3D culture
PDGF signaling
imatinib
medial thickening
pulmonary arterial hypertension
pulmonary artery smooth muscle cell
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2020
2020
Historique:
received:
31
01
2020
accepted:
27
04
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
In pulmonary arterial hypertension (PAH), excessive proliferation of pulmonary artery smooth muscle cells (PASMCs) causes vascular medial thickening. Medial thickening is a histopathological hallmark of pulmonary vascular remodeling, the central disease process driving PAH progression. Pulmonary vascular remodeling causes stenosis and/or obstruction of small pulmonary arteries. This leads to increased pulmonary vascular resistance, elevated pulmonary arterial pressure, and ultimately right heart failure. To improve the survival of PAH patients, which remains at approximately 60% at 3 years after diagnosis, the development of novel PAH-targeted drugs is desired. To this end, a detailed understanding of the mechanisms underlying excessive PASMC proliferation and the medial thickening that ensues is necessary. However, a lack of
Identifiants
pubmed: 32509756
doi: 10.3389/fbioe.2020.00482
pmc: PMC7251161
doi:
Types de publication
Journal Article
Langues
eng
Pagination
482Informations de copyright
Copyright © 2020 Morii, Tanaka, Izushi, Nakao, Yamamoto, Matsubara, Kano and Ogawa.
Références
Eur Respir Rev. 2017 Dec 20;26(146):
pubmed: 29263173
Adv Exp Med Biol. 2010;661:435-46
pubmed: 20204747
N Engl J Med. 2004 Sep 30;351(14):1425-36
pubmed: 15459304
Hypertension. 1997 Jan;29(1 Pt 2):350-5
pubmed: 9039126
Basic Res Cardiol. 2005 Mar;100(2):131-8
pubmed: 15739122
Circ Res. 2018 Jun 22;123(1):73-85
pubmed: 29691232
Am J Pathol. 2019 Jun;189(6):1133-1144
pubmed: 30926336
Int J Cardiol. 2012 Aug 23;159(2):100-6
pubmed: 21376411
Circulation. 2005 Sep 20;112(12):1806-12
pubmed: 16157769
Expert Opin Investig Drugs. 2012 Jan;21(1):119-34
pubmed: 22074410
Pulm Circ. 2013 Dec;3(4):739-56
pubmed: 25006392
J Cardiovasc Pharmacol. 2006 Feb;47(2):250-5
pubmed: 16495763
Circulation. 2010 Jul 13;122(2):156-63
pubmed: 20585011
Am J Physiol Lung Cell Mol Physiol. 2012 Feb 15;302(4):L363-9
pubmed: 21964406
Genes Dev. 2008 May 15;22(10):1276-312
pubmed: 18483217
J Cell Mol Med. 2010 Jan;14(1-2):42-50
pubmed: 19968734
Clin Cancer Res. 2002 May;8(5):935-42
pubmed: 12006504
Arterioscler Thromb Vasc Biol. 2015 May;35(5):1236-45
pubmed: 25745058
J Pharmacol Exp Ther. 2017 Jul;362(1):186-199
pubmed: 28476928
Chest. 2012 Aug;142(2):448-456
pubmed: 22281797
Eur J Cardiothorac Surg. 2006 Sep;30(3):499-507
pubmed: 16870458
J Heart Lung Transplant. 2015 Nov;34(11):1366-75
pubmed: 26210752
Am J Respir Crit Care Med. 2004 Nov 15;170(10):1101-7
pubmed: 15317671
Biomaterials. 2019 Feb;192:355-367
pubmed: 30476717
J Cell Sci. 2012 Jul 1;125(Pt 13):3015-24
pubmed: 22797912
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S10-9
pubmed: 19555853
Eur Respir J. 2009 Sep;34(3):662-8
pubmed: 19324949
Am J Respir Crit Care Med. 2010 Nov 1;182(9):1171-7
pubmed: 20581169
J Clin Invest. 2005 Oct;115(10):2811-21
pubmed: 16200212
Cardiovasc Res. 2018 Mar 15;114(4):551-564
pubmed: 29385432
Circulation. 2013 Mar 12;127(10):1128-38
pubmed: 23403476
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S20-31
pubmed: 19555855
Expert Opin Ther Targets. 2012 Nov;16(11):1055-63
pubmed: 22924478
Am J Physiol Lung Cell Mol Physiol. 2008 Oct;295(4):L648-57
pubmed: 18708631
Am J Respir Crit Care Med. 2008 Jul 1;178(1):81-8
pubmed: 18420966
Am J Physiol Lung Cell Mol Physiol. 2009 Dec;297(6):L1013-32
pubmed: 19748998
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545971